Tesaro, Inc., a prominent biopharmaceutical company headquartered in the United States, is dedicated to advancing cancer treatment through innovative therapies. Founded in 2010, Tesaro has made significant strides in the oncology sector, particularly in the development of targeted therapies and immuno-oncology solutions. The company’s flagship product, Zejula (niraparib), is a groundbreaking treatment for ovarian cancer, distinguished by its ability to provide maintenance therapy for patients with recurrent disease. Tesaro's commitment to research and development has positioned it as a leader in the oncology market, with a focus on improving patient outcomes and quality of life. With a strong presence in North America and Europe, Tesaro continues to expand its portfolio, aiming to address unmet medical needs in cancer care. Its dedication to innovation and patient-centric solutions underscores its reputation as a key player in the biopharmaceutical industry.
We don't have data for Tesaro, Inc., but we can show you information about their parent organization instead.
View parent company